Aesculus Bio ApS: Financial statements 2022
CVR: 40560866
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Aesculus Bio ApS (CVR 40560866) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -25,019 and a net result of DKK -14,524 compared with DKK 73,545 the year before. Equity in the 2022 report amounted to DKK 152,086. The solvency ratio was 50.6%.
- Gross Profit
- DKK -25,019
- Profit/Loss
- DKK -14,524
- Equity
- DKK 152,086
- Total Assets
- DKK 300,404
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -25 t. | -15 t. | 152 t. | - |
| 2021 | - | 88 t. | 74 t. | 167 t. | - |
| 2020 | - | -12 t. | -15 t. | 93 t. | - |
Official annual report
Keep an eye on Aesculus Bio ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 8, 2022, Benjamin Anderschou Holbech Jensen is registered as an owner of Aesculus Bio ApS with an ownership share of 15%.
Aesculus Bio ApS has published its annual report for 2021. Gross profit came to DKK 87,677, and the net result was DKK 73,545.
About Aesculus Bio ApS
Aesculus Bio ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Benjamin Anderschou Holbech Jensen. The board consists of Peter Hviid Nordkild (chair) and Benjamin Anderschou Holbech Jensen. The company is owned by Benjamin Anderschou Holbech Jensen, PN INVESTMENT ApS and Jan Wehkamp. In 2025, the company reported a gross profit of DKK -154,862 and a net result of DKK -129,437 compared with DKK -45,866 the year before. Equity in the 2025 report amounted to DKK -34,097.